American Bio Medica Offers Test for Buprenorphine

KINDERHOOK, N.Y. -- (BUSINESS WIRE) -- Jan. 3, 2006 -- American Bio Medica Corporation (NASDAQ: ABMC) today announced they have begun offering a point of collection drug screen that detects the presence or absence of buprenorphine in a urine specimen. Buprenorphine is a drug being used in a new office-based treatment for addiction to prescription pain relievers and other opiate drugs, including heroin. While the drug is intended to aid in addiction treatment, buprenorphine is potent (20 to 50 times the analgesic potency of morphine), has a long duration of action, and does not need to be injected, therefore the potential for abuse is high.

Stan Cipkowski, ABMC Chief Executive Officer stated, "Many of our customers in Europe indicated a need for a screen for buprenorphine so we developed a test to meet those needs. It is available in a single test or can be inserted into one of our multi panel devices. This is just another example of ABMC's ability to customize our products to meet the ever changing needs of the drugs of abuse testing market."

The product is currently available to non-clinical markets. ABMC plans to submit their screen for buprenorphine to the FDA for clinical marketing clearance.

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), Rapid TEC(R), RDS(R) InCup and Rapid TOX(TM) products test for the presence or absence of drugs of abuse in urine, while OralStat(R) tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader(TM) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2004, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

    CONTACT: ABMC
             Stan Cipkowski, 800-227-1243, Ext 106
             or
             BPC Financial Marketing
             John Baldissera, 800-368-1217

    SOURCE: American Bio Medica Corporation